Research programme: anticancer protease inhibitors - CuracyteAlternative Names: CJ-463 uPA inhibitor; CJ-730 matriptase inhibitor; Matriptase inhibitors - Curacyte; Urokinase plasminogen activator inhibitors - Curacyte
Latest Information Update: 03 Aug 2007
At a glance
- Originator Curacyte AG
- Class Small molecules
- Mechanism of Action Hepatocyte growth factor inhibitors; Matriptase inhibitors; Peptide hydrolase inhibitors; Urokinase-type plasminogen activator inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Oct 2005 Preclinical trials in Cancer in Germany (unspecified route)